Aquestive Therapeutics vs Cumberland Pharmaceuticals
Aquestive Therapeutics reported revenue of $44 million in fiscal 2025, about the same as Cumberland Pharmaceuticals' $44 million in fiscal 2025. Aquestive Therapeutics' revenue fell 22.6% in its latest year, and Cumberland Pharmaceuticals' grew 17.6%. Aquestive Therapeutics had an operating margin of -159.5%, against -6.3% at Cumberland Pharmaceuticals. Free cash flow was −$53 million at Aquestive Therapeutics and $5 million at Cumberland Pharmaceuticals.
Side by side
| Aquestive Therapeutics | Cumberland Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $44M | $44M |
| Revenue growth | −22.6% | 17.6% |
| Revenue growth a year, last 5 years | −0.6% | 3.5% |
| Gross margin | 58.4% | 85.0% |
| Operating margin | −159.5% | −6.3% |
| Net margin | −188.1% | −6.4% |
| Free cash flow | −$53M | $5M |
| Free cash flow margin | −119.0% | 10.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 23.3% | 5.7% |
| Last close | $3.71 | $6.30 |
| P/E at the last close | — | 1.4× |
| Insider trades, last 12 months | sold $2.3 million | — |
| Piotroski F-score | 2 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Aquestive TherapeuticsCumberland Pharmaceuticals
Operating margin
Percent of revenue
Aquestive TherapeuticsCumberland Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aquestive TherapeuticsCumberland Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aquestive Therapeutics and Cumberland Pharmaceuticals pages.